On Feb. 20, Cantor Fitzgerald analyst Eric Schmidt restated his aggressive price target for Biogen, (BIIB 1.82%) estimating that the biopharmaceutical stock will rise by 39% to reach roughly $311. One driver for that anticipated growth is the company's newly launched drug called Leqembi, which aims to treat Alzheimer's disease. But Leqembi is just one of four recent launches, with the other medicines treating conditions like postpartum depression and amyotrophic lateral sclerosis (ALS).Schmidt is likely to ...

The latest trading session saw Biogen Inc. (BIIB) ending at $221.74, denoting a -0.98% adjustment from its last day's close. The stock's change was less than the S&P 500's daily loss of 0.17%. On the other hand, the Dow registered a loss of 0.06%, and the technology-centric Nasdaq decreased by 0.55%.Coming into today, shares of the company had lost 9.37% in the past month. In that same time, the Medical sector gained 5.93%, while the S&P 500 gained 3.98%.The investment community will be closely monitoring t ...

SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe1With QALSODY, Biogen has advanced the role of neurofilament in the development of new medicines for ALS, with the potential to accelerate further discovery in the field CAMBRIDGE, Mass., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommend ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-19311 BIOGEN INC. (Exact name of registrant as specified in its charter) Delaware 33-0112644 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identi ...

Biogen Inc. (NASDAQ:BIIB) Q4 2023 Earnings Conference Call February 13, 2024 8:00 AM ET Company Participants Chuck Triano - Head of Investor Relations Chris Viehbacher - President and Chief Executive Officer Priya Singhal - Head of Development Mike McDonnell - Chief Financial Officer Conference Call Participants Marc Goodman - Leerink Partners Salveen Richter - Goldman Sachs Umer Raffat - Evercore ISI Evan Seigerman - BMO Capital Markets Phil Nadeau - TD Cowen Michael Yee - Jefferies Colin Bristow - UBS Chr ...

Biogen (BIIB) reported fourth-quarter 2023 adjusted earnings per share (EPS) of $2.95, which missed the Zacks Consensus Estimate of $3.16. Earnings declined 27% year over year. On a constant currency basis, earnings were flat.Total revenues came in at $2.39 billion, down 6% on a reported basis (5% on a constant-currency basis) from the year-ago quarter due to lower sales of all key drugs, multiple sclerosis (MS) drugs like Tecfidera and Tysabri as well as spinal muscular atrophy drug, Spinraza. Sales missed ...

Biogen Inc. (BIIB) reported $2.39 billion in revenue for the quarter ended December 2023, representing a year-over-year decline of 6.2%. EPS of $2.95 for the same period compares to $4.05 a year ago.The reported revenue represents a surprise of -2.88% over the Zacks Consensus Estimate of $2.46 billion. With the consensus EPS estimate being $3.16, the EPS surprise was -6.65%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine ...

Biogen Inc. (BIIB) came out with quarterly earnings of $2.95 per share, missing the Zacks Consensus Estimate of $3.16 per share. This compares to earnings of $4.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -6.65%. A quarter ago, it was expected that this company would post earnings of $3.99 per share when it actually produced earnings of $4.36, delivering a surprise of 9.27%.Over the last four quarters, the company has s ...

Q4 and Full Year 2023 Financial Results and Business Update Non-GAAP financial information This presentation and the discussions during this conference call include certain financial measures that were not prepared in accordance with accounting principles generally accepted in the U.S. (GAAP), including adjusted net income, adjusted diluted earnings per share, revenue growth at constant currency, which excludes the impact of changes in foreign exchange rates and hedging gains or losses, and free cash flow, ...

Biogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago, as it recorded charges related to dropping its controversial Alzheimer's drug Aduhelm and as sales slumped in its multiple sclerosis therapies, the company's biggest drug category.Biogen booked sales of $2.39 billion for the quarter, down 6% from the same period a year ago. Revenue from multiple sclerosis products fell 8% to $1.17 billion as the therapies face competition from cheaper generics. The results come as the ...